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Purpose: To improve upon self-reported glaucoma status in population-based cohorts by developing a 
questionnaire-based proxy incorporating self-reported status in conjunction with glaucoma-specific visual 
complaints. 
Methods: A vision specific questionnaire, including questions from the National Eye Institute Visual 
Functioning Questionnaire-25 (NEI-VFQ-25) was administered to 79,866 Lifelines participants, a 
population-based cohort study in the Northern Netherlands. We compared NEI-VFQ-25 responses 
between ‘definite’ glaucoma cases (n=90; self-reported surgical cases) and an age- and gender-matched 
subset of controls (n=1,800) to uncover glaucoma-specific visual complaints, using a case-control logistic 
regression. We defined ‘probable glaucoma’ as both self-reported disease status and visual complaints, 
and ‘possible glaucoma’ as either. To evaluate the resulting proxy, we determined age-stratified glaucoma 
prevalences in the remaining cohort and compared the result to the literature. 
Results: Per unit increase in the vision subscales (range 0-100) distance, peripheral, and low-luminance, 
we observed significantly increased odds of definite glaucoma (2% [P=0.03], 4% [P=1.2*10-8], and 2% 
[P=0.02], respectively); the associated area under the curve was 0.73. We identified 300 probable and 
3,015 (1,434 by self-report) possible glaucoma cases. Standardized prevalences of definite, probable, and 
possible glaucoma for 55+ were 0.4, 1.1, and 7.3%, respectively. For self-reported glaucoma (combining 
definite, probable, and possible by self-report), this was 5.2%. 
Conclusions: The combination of self-reported glaucoma status and visual complaints can be used to 
capture glaucoma cases in population-based settings. The resulting prevalence of combined definite and 
probable glaucoma (1.5%) appears to be more consistent with previous reports than the prevalence 





Open-angle glaucoma (OAG) is an adult-onset progressive eye disease that can eventually lead to 
irreversible blindness, and is the second leading cause of permanent visual impairment among the elderly 
worldwide.1 Hallmarks of glaucomatous damage are excavation of the optic nerve head (ONH), thinning 
of the retinal nerve fibre layer (RNFL), and loss of retinal ganglion cells (RGCs).2 These structural 
changes can be observed with fundoscopy, fundus photography, as well as optical coherence tomography, 
and lead to defects in the visual field that can be identified via perimetry.3 An epidemiological definition 
of glaucoma was developed in 2002 by the International Society for Geographical and Epidemiological 
Ophthalmology (ISGEO), and is still routinely used.4 Briefly, glaucoma is classified in three categories, 
primarily based on the presence of structural and functional abnormalities, with IOP readings and medical 
history used as additional information. Phenotyping all participants for glaucoma in epidemiological 
studies according to the ISGEO definition requires costly and time-consuming ophthalmic assessments. 
While doable - and highly valuable - in studies with 1,000-10,000 participants,5–9 current enrollment sizes 
can exceed 100,000 participants,10,11 driving the search for innovative, data-driven solutions.  
 
One solution for phenotyping participants in large datasets is the use of questionnaire data. Currently in 
the UK-biobank, a population-based cohort, glaucoma is classified via self-reported status.12 While 
successful for associating glaucoma with socioeconomic status13, relying on a self-reported diagnosis has 
limitations. First, half of the glaucoma patients are unaware of their disease status.14–16 Second, and 
possibly more important, there is ocular hypertension, a condition with a much higher prevalence than 
glaucoma and often mistaken as glaucoma by the patient. Ocular hypertension is a risk factor for 
glaucoma, but the majority of these patients will never develop glaucoma, i.e., there are no obvious 
structural changes and their visual function remains intact. Hence, the question is, is it possible to make a 
better questionnaire-based proxy for glaucoma than self-reported disease status only? 
 
Although glaucoma is often considered asymptomatic until end-stage disease, this is actually not the case. 
3 
Many patients, including those with early-stage glaucoma, report problems in extreme luminance settings, 
see Bierings et al17 for recent data and discussion on this topic. These reported subjective visual 
complaints suggest that a questionnaire-based proxy for glaucoma is feasible. The subjective visual 
experience of the glaucoma patient can be evaluated with existing visual function questionnaires and a 
well-known example is the National Eye Institute 25-Item Visual Function Questionnaire (NEI-VFQ-25). 
The NEI-VFQ-25 was developed and validated in a number of populations, and in different ocular 
disorders,18 indicating disease specific response patterns.19,20 
 
The aims of this study were (1) to improve upon self-reported glaucoma status in population-based 
cohorts by developing a questionnaire-based glaucoma proxy that incorporates self-reported status in 
conjunction with glaucoma-specific subjective visual experience, and (2) to evaluate the feasibility of our 
glaucoma proxy in the Lifelines cohort, a large (n=167,000) population-based study conducted in the 
Netherlands. For this purpose, we compared answers to the NEI-VFQ-25 questions between separately 
identified ‘definite’ glaucoma cases and an age- and gender-matched subset of controls, with a 
multivariable case-control logistic regression. Using the resulting coefficients from the regression to 
construct a classification equation, together with information on self-reported glaucoma or high eye 
pressure, we defined ‘probable’ and ‘possible’ glaucoma. As a feasibility check, we used the resulting 
proxy (classification into definite, probable, and possible glaucoma based on questionnaire data) to 






Lifelines is a prospective population-based cohort study of the Northern Netherlands.21 It examines the 
health and health-related behaviours of 167,729 persons, in a unique three-generation design. For this, 
Lifelines employs a broad range of investigative procedures in assessing the biomedical, socio-
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demographic, behavioural, physical, and psychological factors which contribute to the health and disease 
of the general population, with a special focus on multi-morbidity and complex genetics.22 The cohort 
structure, where participants will be followed for at least 30 years, is described fully elsewhere.11 The 
NEI-VFQ-25 questionnaire was administered to all participants aged 18 and older during the first follow-
up visit between 2014-2017, and the first wave of results (n = 79,866 adult participants) was used for this 
study. This sample is similar to the remaining adult portion of the Lifelines cohort measured at baseline, 
59% female vs 58% in the rest of the cohort, and 50.4 years of age compared to 50.8 in the remaining 
population. Those who self-identified as Caucasian were included in the analyses.  
 
The study protocol was approved by the ethics board of the University Medical Center Groningen 
(UMCG) and adhered to the tenets of the Declaration of Helsinki. All participants in Lifelines provided 




We used Part 2 of the NEI-VFQ-25 (‘difficulty with activities’ questions) in combination with self-
reported eye disease status and current or past treatment for proxy development. Table 1 presents the 
questions used in the current study. The NEI-VFQ-25 driving questions were omitted due to excessive 
multicollinearity based on a variance inflation factor cut-off of 5, and missingness that exceeded 5%.23  
 
We used the scoring algorithm developed by Mangione et al to transform initial visual question responses 
to visual subscales.24,25 Initial responses were ranked from 1-6, where a higher score within 1-5 indicates a 
worse visual problem. Response 6 indicates the person stopped the activity due to other reasons, and was 
treated as missing. Responses were transformed to a scale from 0-100; the higher the score, the poorer the 
visual experience. Imputation of missingness was performed for missing data up to five percent.24 
Question 9 in the NEI-VFQ-25 ‘distance vision’ subscale (“Because of your eyesight, how much 
difficulty do you have going down steps, stairs, or curbs in dim light or at night?”) was used to create a 
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low luminance subscale, as glaucoma patients struggle in low luminance situations.17,24 The resulting six 
visual subscales were peripheral (Question 6 in Table 1), distance vision (Questions 4 and 10), near vision 
(Questions 1-3), social functioning vision (Question 7 and 9), colour vision (Question 8), and low 
luminance vision (Question 5). We aimed for primary glaucoma, where glaucoma is not secondary to 
another eye disease. Based on the available information regarding other eye diseases, and the likelihood 
that these diseases could result in secondary glaucoma, we excluded those who underwent surgery or laser 
intervention for diabetic retinopathy (Questions 14 and 18 in Table 1) or surgical intervention for retinal 
detachment (Question 17). Those diagnosed with age-related macular degeneration (AMD) were also 
excluded (Question 11). Although the visual complaint pattern of AMD will differ from that of glaucoma 
patients, it is a common age-related eye disease that might confound our case detection. 
 
From questionnaire data to glaucoma proxy 
 
The development of the glaucoma proxy consisted of three steps. First, as mentioned above, we excluded 
those with a history of diabetic retinopathy, macular degeneration, or retinal detachment, aiming for 
primary glaucoma. Second, we defined and identified ‘definite glaucoma’ in the remaining participants, 
see Figure 1. Third, we sampled an age- and gender-matched subgroup of controls with no self-reported 
eye disease, see Table 2. We compared NEI-VFQ-25 answers between the definite glaucoma cases and 
matched controls, together termed the ‘training population’. From this comparison, and from the answers 
to the additional questions displayed in Table 1, we defined ‘probable’ and ‘possible’ glaucoma. These 
steps together yielded a proxy; a classification into definite, probable, and possible glaucoma, as well as 
unaffected, based on questionnaire data. What now follows are the details of the approach. 
 
Training population; definite glaucoma 
 
Definite glaucoma was defined as a history of an incisional surgical intervention for glaucoma (Question 
16 in Table 1). Subsequently, a group (n=1,800) of 20 random controls per definite glaucoma case was 
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created through propensity scoring of age and gender, using R (matchit with method="nearest", 
exact="gender", and ratio=20).26 This population of definite cases and age- and gender-matched controls 
is now referred to as the ‘training population’, see Figure 1. 
  
Next, a case-control logistic regression of the visual subscales was performed in the training population, 
see Figure 1. The resulting coefficients were used to build a classification equation for glaucoma class 
discrimination. A receiver operator characteristic (ROC) curve was constructed to identify thresholds for 
this class discrimination. Two classification thresholds were obtained. ‘Threshold 1’ was the maximum 
value of the Youden index, i.e., the largest distance between the ROC-curve and the chance line. 
‘Threshold 2’ was more stringent, corresponding to 97.5% specificity on the ROC-curve. 
 
Testing Population; probable and possible glaucoma 
 
The classification equation was then applied to the remaining Lifelines participants, the ‘testing 
population’ (entire cohort excluding those with conflicting eye diseases, the training population controls, 
and those who did not self-identify as Caucasian). Individual regression scores were tested against the 
thresholds described above. Participants with glaucoma-related treatments/diagnosis (Questions 12, 13, 
and 19 in Table 1) and surpassing Threshold 1 were classified as ‘probable’. Participants with glaucoma-
related treatments/diagnosis but not surpassing Threshold 1 were classified ‘possible by self-report’. 
Participants surpassing Threshold 2 without glaucoma treatment/diagnosis were considered ‘possible by 
complaint’. The two classes of ‘possible’ were then combined. The remaining participants were classified 
as ‘unaffected’ (see Figure 1). 
 
Performance of glaucoma proxy 
 
To determine the feasibility of this proxy in a population-based setting, the prevalence of glaucoma was 
obtained. Age-stratified (up to 55, 55-69, 70+) glaucoma prevalences were obtained through the number 
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of definite, probable, and possible cases divided by the total number of participants in the concerning age-
stratum. Prevalences were then standardized via the Dutch 2018 population census (obtained from 
Statistics Netherlands, https://opendata.cbs.nl/statline/#/CBS/en/dataset/37296eng/table?fromstatweb, 




All analyses were performed using SPSS (version 24.0.0.2) and R (version 3.4.2). A P value of 0.05 or 




Of the 79,866 submitted questionnaires, 79,845 participants provided usable data. The remaining 21 
participants did not complete the eye portion of the questionnaire. Ages ranged from 19 to 94, with a 
mean age (standard deviation) of 50.4 (12.6) years. In total, 2,339 participants were removed due to either 
conflicting eye diseases, or for identifying other than Caucasian, resulting in 77,506 participants (Figure 
1).  
 
In total there were 111 participants who had a history of glaucoma surgery. After excluding those who 
underwent laser treatment or surgery for diabetes (n=2), and/or surgery for retinal detachment (n=10; 1 
overlapping with diabetic laser/surgery treatment), and/or who had AMD (n=13; 3 overlapping with 
retinal detachment surgery), 90 cases of definite glaucoma were identified within the Lifelines population. 
The mean (standard deviation) age of the definite glaucoma cases was 61.7 (12.6) years. The age of the 
definite glaucoma cases was significantly different than the rest of the cohort (paired t-test P=6.4x10-15); 
after selecting 20 age- and gender- matched controls (n = 1,800), age was not significantly different 
between cases and controls (paired t-test P=0.89). Table 2 displays the mean visual subscale scores of the 
definite glaucoma cases and the age- and gender-matched controls. In the univariable analyses, all 
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subscales were highly significantly different between cases and controls. In the multivariable analysis, per 
one unit increase in the vision subscales (range 0-100) of distance, peripheral, and low-luminance vision, 
we observed significantly increased odds of definite glaucoma of 2% (P=0.03), 4% (P=1.2*10-8), and 2% 
(P=0.02), respectively. Figure 2 shows the ROC curve for the logistic regression. The area under the 
curve (AUC) was 0.73. The corresponding classification equation was: 
  
𝑦 = (−0.003 ∗ 𝑛𝑒𝑎𝑟) + (0.024 ∗ 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 ) + (0.038 ∗ 𝑝𝑒𝑟𝑖𝑝ℎ𝑒𝑟𝑦 ) + (−0.009
∗ 𝑠𝑜𝑐𝑖𝑎𝑙 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛) 
 +(−0.010 ∗ 𝑐𝑜𝑙𝑜𝑢𝑟) + (0.015 ∗ 𝑙𝑜𝑤 𝑙𝑢𝑚𝑖𝑛𝑎𝑛𝑐𝑒 ) − 3.76. 
 
Threshold 1 was 0.08 with an associated sensitivity of 50.0% and specificity of 89.8%. Threshold 2 was 
0.17 with an associated sensitivity of 30.0% at the required specificity of 97.5%. 
 
In total, 300 participants were classified as probable glaucoma and 3,015 as possible glaucoma. Of these 
3,015 possible glaucoma cases, 1,434 participants were classified as possible by self-report and 1,581 as 




Table 3 presents the prevalence of glaucoma, stratified by age and glaucoma category. Age-stratified 
prevalences ranged from 0.06% of definite cases in the youngest age stratum up to approximately 9% of 
possible cases in the oldest age stratum. The raw prevalences of definite, probable, and possible glaucoma 
in the 55+ population were 0.2, 0.9, and 6.6%, with corresponding standardized prevalences of 0.4, 1.1, 
and 7.3%, respectively. For self-reported glaucoma (combining definite, probable, and possible by self-





We created a questionnaire-based glaucoma proxy for use in population-based epidemiology; the 
resulting glaucoma categories are definite, probable, possible, and unaffected. Categorization is based on 
a history of glaucoma surgery, self-reported glaucoma and ocular hypertension which includes self-
reported medical treatment for glaucoma/ocular hypertension, as well as the presence or absence of 
glaucoma-specific visual complaints according to the NEI-VFQ-25. Based on this proxy, the standardized 
prevalence of combined definite and probable glaucoma in the 55+ population participating in Lifelines is 
approximately 1.5%. 
 
Our definitions of definite, probable, and possible glaucoma differ, inevitably, from the ISGEO criteria, 
and do not correspond one-to-one to clinical diagnoses. For the ISGEO Category 1 glaucoma diagnosis 
(the strictest category), glaucomatous visual field loss (GVFL) and glaucomatous optic neuropathy 
(GON) are required. In clinical settings, patients who have undergone glaucoma surgery likely fulfill the 
ISGEO Category 1 diagnosis criteria; many medically treated patients fulfill these criteria as well. Hence, 
our definite cases are a subset of the ISGEO Category 1 diagnosis cases. As mentioned in the Introduction 
section, it is not possible to simply rely on self-reported disease status to define glaucoma in population-
based epidemiology, as the prevalence of ocular hypertension is much higher than that of glaucoma, and 
both are easily mixed-up by patients.27 To address this, we combined self-reported disease 
status/treatment with glaucoma-specific visual complaints; this combination was denoted as probable 
glaucoma. In the Rotterdam Study, the prevalence of glaucoma was 0.8% in the 55+ population when 
using ISGEO Category 1 diagnosis (GVFL and GON).15 If we extend the glaucoma classification to what 
was used more recently in the Rotterdam Study, 28,29 from ISGEO Category 1, to GVFL with or without 
GON together with ISGEO Category 2 diagnosis (GON only, but with a stricter criterion), the prevalence 
of glaucoma in the Rotterdam Study is 3.2%. As all participants receive a full eye exam, the Rotterdam 
Study identifies both patients who are aware of their disease status, as well as those with undiagnosed 
glaucoma.30 As mentioned in the Introduction section, only half of the glaucoma patients are aware of 
their disease status, thus the prevalence of 3.2% in the Rotterdam Study corresponds quite well with our 
1.5%, given that our definitions of definite and probable glaucoma imply awareness. As Lifelines and the 
10 
Rotterdam Study are both based in the Netherlands and comprise Caucasian participants only, our proxy 
provides a prevalence estimate that is consistent with diagnosed glaucoma if we combine definite and 
probable glaucoma. 
 
In the UK Biobank, the age-stratified prevalence of self-reported glaucoma was 0.48% for participants 
40-49 years of age, 1.18% for those 50-59 years of age, and 2.68% for those aged 60-69.13 Considering 
that glaucoma is generally diagnosed in the sixth decade of life, the UK Biobank population is relatively 
young.31 To compare these prevalences to our dataset, we calculated the corresponding prevalences for 
the combined definite and probable categories. This yielded a prevalence of 0.27% for participants 40-49 
years of age, 0.37% for those 50-59 years of age, and 1.29% for those aged 60-69. Given that the 
prevalence of the combined definite and probable categories appears to approximate that of diagnosed 
glaucoma in the general population quite well (see previous paragraph), the self-report approach of the 
UK biobank seems to yield an overestimation of the actual glaucoma prevalence (assuming the same 
glaucoma prevalence in the Caucasian populations of the UK and the Netherlands). As mentioned in the 
Introduction section, spurious inclusion of ocular hypertension could explain this overestimation. To 
compare, the prevalence of self-reported glaucoma in our study (combined definite, probable, and 
possible by self-report categories) was 1.50% for participants 40-49 years of age, 2.40% for those 50-59 
years of age, and 4.50% for those aged 60-69. These values seem higher than those reported by the UK 
biobank. This difference likely arose as we explicitly mentioned ocular hypertension as part of the self-
reported glaucoma question (Question 12 in Table 1), where the UK biobank did not (The question for 
participants was, “Has a doctor told you that you have any of the following problems with your eyes” 
with “glaucoma” in a list of ocular disorders).  
 
In Lifelines, participants not aware of their disease could have been captured in our study as ‘possible 
glaucoma based on complaint’. We obtained 1,581 possible by complaint, clearly exceeding the expected 
number (~400) based on a disease awareness of 50%. This category is presumably a mixture of glaucoma 
cases and false positives. Similarly, the possible glaucoma by self-report category is likely made up of 
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participants with early, asymptomatic glaucoma detected by chance, as well as glaucoma suspects, i.e., 
those with ocular hypertension, or, for example, those followed-up because of relatives with glaucoma. 
Depending on the purpose of future studies using our proxy, the possible glaucoma category could be 
excluded rather than being attributed to either cases or controls. 
 
To evaluate the robustness of our approach to uncover the glaucoma-specific visual complaints, we re-
analyzed our data utilizing linear discriminant analysis (LDA). The same NEI-VFQ-25 subscales were 
identified as relevant to glaucoma and no statistical difference was identified between the AUC of logistic 
regression, and that of LDA (AUC for logistic regression = 0.73, AUC for LDA = 0.73, P=0.76).32 The 
LDA categorization was as follows, 366 for probable (290 overlapping with logistic regression), 1,368 for 
possible by self-report (1,358 overlapping with logistic regression), and 1,907 possible by complaint 
(1,563 overlapping with logistic regression). The LDA was less conservative in classifying ‘probable’ and 
‘possible glaucoma by complaint’, however, identified cases largely overlapped between the two 
approaches. The large overlap of glaucoma categorization for both approaches suggests robustness of our 
approach.  
 
We aim to study primary open-angle glaucoma. Potentially, our data are contaminated with primary 
angle-closure glaucoma, pseudoexfoliative glaucoma, secondary glaucoma, or other ocular disorders that 
may present as glaucoma through the subjective visual complaints. Fortunately, primary angle-closure 
glaucoma and pseudoexfoliative glaucoma have a significantly lower prevalence in our Caucasian study 
population.30 A systematic review reported the prevalence ratio of primary open-angle glaucoma 
compared to primary angle-closure glaucoma in European-derived populations to be approximately 10:1 
(range: 2.6:1 to 20.7:1).33 Similarly, at the population level, secondary glaucoma is rare compared to 
primary open-angle glaucoma,34 but this might be different in a clinical setting.35 So, to further reduce the 
probability of spuriously including secondary glaucoma, we excluded those who underwent surgery or 
laser intervention for diabetic retinopathy, or surgical intervention for retinal detachment. Finally, retinal 
dystrophies like retinitis pigmentosa present with a similar subjective vision loss pattern to glaucoma, i.e., 
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deficits in peripheral and low luminance vision, but are rare in the general population with an estimated 
prevalence below 0.1% in the Netherlands.36,37 
 
A major strength of this study was the stringent inclusion criterion for definite glaucoma, being a history 
of glaucoma surgery, which enabled us to quantify the glaucomatous visual impairment very clearly. A 
limitation is that the history of glaucoma surgery was self-reported, and may have been reported 
erroneously. Due to the nature and privacy of the data, medical records were unavailable to us. As such, 
the subjective visual complaints obtained from this study may be moderated by misclassification, 
resulting in an underestimation of the power of a questionnaire-based glaucoma proxy. Specifically, 
mixing-up glaucoma surgery and cataract surgery may have occurred. To address this, cataract surgery 
was addressed separately in the questionnaire, before glaucoma surgery. The use of 20 age- and gender-
matched controls per case allows us to surmise that the vision loss captured in the regression is due to 
glaucoma, and not general ageing. Our method was developed in a Caucasian population. It is unknown if 
the proxy can be used in populations of different ethnicities. However, it was reported that glaucoma 
patients of African descent have no difference when compared to Caucasian glaucoma patients with 
respect to the NEI-VFQ-25 visual subscales.38 Although no direct comparison to a Caucasian population 
was made, Korean glaucoma patients also have reported significant issues with the peripheral and social 
function vision subscales,39 and in a case-control comparison of Latino-Americans, significant differences 
were observed in all visual subscales.40 A limitation of this study is the exclusion of participants with 
diabetic retinopathy, retinal detachment, and AMD - intentionally done to avoid including participants 
with secondary glaucoma. As such, no conclusions can be made regarding glaucoma in patients with 
ophthalmic comorbidity. 
 
In conclusion, this study demonstrated that glaucoma patients have significantly poorer subjective visual 
experiences than their age- and gender-matched peers in terms of distance, low luminance, and peripheral 
vision as assessed by questionnaires. Their subjective visual experience, together with self-reported 
disease status, successfully guides the creation of a classification equation to rank others’ glaucoma proxy 
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status. The resulting prevalence appears to be more consistent with previous glaucoma prevalence 
literature than a prevalence estimate based only on self-report. The proxy opens opportunities for 
glaucoma research within large-scale population-based settings, where in-depth phenotyping of all 
participants is not easily feasible.  
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Tables 
Table 1. Question list, derived from the National Eye Institute 25-Item Visual Function Questionnaire and related 
medical questions, used for the glaucoma proxy creation and application 
 
Question  Answer type Visual Subscale 
In the past month have you had trouble…  -- -- 
1. reading ordinary print in newspapers Ordinal Near 
2. doing work or hobbies that require you to see well up close , such as cooking, sewing, fixing things around 
the house, or using hand tools 
Ordinal Near 
3. finding something on a crowded shelf Ordinal Near 
4. reading street signs or the names of stores Ordinal Distance 
5. Going down steps, stairs, or curbs in dim light or at night Ordinal Low Luminance 
6. Noticing objects off to the side while you are walking along Ordinal Peripheral 
7. Seeing how people react to the things you say Ordinal Social 
8. Picking out and matching your own clothes Ordinal Colour 
9. Visiting people in their homes, at parties, or in restaurants Ordinal Social 
10. Going out to see movies, plays, or sporting events Ordinal Distance 
Has an ophthalmologist diagnosed you with…  -- -- 
11. Macular degeneration yes/no  
12. Glaucoma/high eye pressure yes/no  
Did you ever have a laser treatment for your eyes (y/n)? If yes, for which condition did you have laser 
treatment? 
-- -- 
13. Glaucoma/high eye pressure yes/no  
14. Diabetes yes/no  
(other response options were: after cataract, diabetes, to get rid of glasses/contact lenses, other, don’t 
remember) 
  
Did you ever have eye surgery for your eyes (y/n)? If yes, for which condition did you have eye surgery? -- -- 
16. Glaucoma/high eye pressure yes/no  
17. Retinal detachment yes/no  
18. Diabetes yes/no  
(other response options were: cataract, to get rid of glasses/contact lenses, other, don’t remember)   
Are you currently using eye drops/gel? If yes, for which condition are you using eye drops/gel? -- -- 
19. Glaucoma yes/no  
(other response options: allergy, dry eyes, other, don’t remember)   
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Table 2. Baseline characteristics and visual subscale results (NEI-VFQ-25; range from 0-100, where a higher score 



















Mean (SD) age (years) 
 
61.7 (12.9) 61.9 (12.8) 0.99 -- -- 
 
Gender (% female) 
 
47 (52.2%) 940 (52.2%) 1.00 -- -- 
Visual 
Subscale 































* = within the 90 definite glaucoma cases, there was one missing response in the peripheral vision subscale and one 
in the low luminance subscale; † = within the 1,800 controls, there were six missing responses for near, three for 
distance, seven for peripheral, seven for social functioning, 11 for colour vision, and seven for low luminance 
subscales; ‡ = from independent-sample t-tests;  ¶ = per unit increase in subscale score from a univariable logistic 
regression, adjusted for all other visual subscales; § = per unit increase in subscale score from a multivariable logistic 







Table 3. Age-stratified glaucoma prevalences within the Lifelines cohort (n=75,706) 
 
 Prevalence, % (n) 
Age n Definite Probable Possible 
18-54 51,202 0.06 (30) 0.15 (77) 2.73 (1,396) 
55-69 19,688 0.15 (29) 0.77 (143) 5.93 (1,167) 
70+ 4,816 0.64 (31) 1.66 (80) 9.39 (452) 













Figure 2: Receiver operator characteristic curve indicating the predictive ability of the NEI-VFQ-25 subscales to 
differentiate between definite glaucoma and age- and gender- matched healthy controls within the Lifelines cohort.   
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